Skip to main content

Table 1 MFD exhibits anti-fibrotic potential by decreasing mouse hepatic fibrosis in vivo

From: Moniliformediquinone as a potential therapeutic agent, inactivation of hepatic stellate cell and inhibition of liver fibrosis in vivo

 

Inflammation

Degeneration

Hepatocyte necrosis

Fibrosis

Control

MFD alone

 

CCl4 alone

+++

++

+++

+++

CCl4 + MFD (0.1 mg/kg)

+++

++

+++

++

CCl4 + MFD (0.5 mg/kg)

++

+

+

+